New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
12:47 EDTIPSEYIpsen, Galderma increase collaboration for Dysport in new territories
Ipsen and Galderma announced that their collaboration for the promotion and distribution of Dysport, Ipsenís botulinum toxin type A in aesthetic indications, has been extended. Both companies renewed their collaboration in Brazil and Argentina and extended their partnership to Australia where Galderma has the exclusive promotion and distribution rights for Ipsenís Dysport in glabellar lines indication. Both companies also entered into a co-promotion agreement in South Korea where Galderma and Ipsen will co-promote Dysport and Restylane.
News For IPSEY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
05:15 EDTIPSEYActive Biotech AB, Ipsen discontinue development of tasquinimod
Active Biotech (ACTI) and Ipsen (IPSEY) announced top line results of the 10TASQ10 study. While the study showed that tasquinimod reduced the risk of radiographic cancer progression or death compared to placebo in patients with metastatic castration resistant prostate cancer, or mCRPC, who have not received chemotherapy, tasquinimod did not extend overall survival. Efficacy results together with preliminary safety data do not support positive benefit risk balance in this population. Therefore the companies have decided to discontinue all studies in prostate cancer. Full results will be presented at an upcoming scientific conference.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use